BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yamada A, Sasada T, Noguchi M, Itoh K. Next-generation peptide vaccines for advanced cancer. Cancer Sci. 2013;104:15-21. [PMID: 23107418 DOI: 10.1111/cas.12050] [Cited by in Crossref: 96] [Cited by in F6Publishing: 101] [Article Influence: 8.7] [Reference Citation Analysis]
Number Citing Articles
1 Waki K, Ozawa M, Yamada A. Suppression of high mobility group box 1 in B16F10 tumor does not inhibit the induction of neoantigen-specific T cells. Cancer Sci 2022. [PMID: 36057084 DOI: 10.1111/cas.15563] [Reference Citation Analysis]
2 Motamedi Dehbarez F, Mahmoodi S. Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma. Iran J Med Sci 2022;47:558-65. [PMID: 36380977 DOI: 10.30476/IJMS.2021.90916.2199] [Reference Citation Analysis]
3 Jiang C, Li J, Zhang W, Zhuang Z, Liu G, Hong W, Li B, Zhang X, Chao C. Potential association factors for developing effective peptide-based cancer vaccines. Front Immunol 2022;13:931612. [DOI: 10.3389/fimmu.2022.931612] [Reference Citation Analysis]
4 Li S, Xing R, van Hest JCM, Yan X. Peptide-based supramolecular assembly drugs toward cancer theranostics. Expert Opin Drug Deliv 2022. [PMID: 35748126 DOI: 10.1080/17425247.2022.2093855] [Reference Citation Analysis]
5 Li S, Wu J, Li X, Chen J, Wang C. Biomaterial-enhanced cancer vaccines. Materials & Design 2022;218:110720. [DOI: 10.1016/j.matdes.2022.110720] [Reference Citation Analysis]
6 Hamley IW. Peptides for Vaccine Development. ACS Appl Bio Mater 2022. [PMID: 35195008 DOI: 10.1021/acsabm.1c01238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Yokomizo K, Waki K, Ozawa M, Yamamoto K, Ogasawara S, Yano H, Yamada A. Knockout of high-mobility group box 1 in B16F10 melanoma cells induced host immunity-mediated suppression of in vivo tumor growth. Med Oncol 2022;39:58. [PMID: 35150340 DOI: 10.1007/s12032-022-01659-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Alexandridi M, Mazej J, Palermo E, Hiscott J. The Coronavirus Pandemic – 2022: Viruses, Variants & Vaccines. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.02.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zhu L, Shi Y, Xiong Y, Ba L, Li Q, Qiu M, Zou Z, Peng G. Emerging self-assembling peptide nanomaterial for anti-cancer therapy. J Biomater Appl 2021;:8853282211027882. [PMID: 34180306 DOI: 10.1177/08853282211027882] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Ohno Y, Ohshima S, Miyamoto A, Kametani F, Ito R, Tsuda B, Kasama Y, Nakada S, Kashiwagi H, Seki T, Yasuda A, Ando K, Ito M, Tokuda Y, Kametani Y. HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice. Sci Rep 2021;11:12798. [PMID: 34140620 DOI: 10.1038/s41598-021-92311-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Lee J, Uy BR, Liau LM. Brain Tumor Vaccines. Neurosurg Clin N Am 2021;32:225-34. [PMID: 33781504 DOI: 10.1016/j.nec.2021.01.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhang J, Sun H, Gao C, Wang Y, Cheng X, Yang Y, Gou Q, Lei L, Chen Y, Wang X, Zou Q, Gu J. Development of a chitosan-modified PLGA nanoparticle vaccine for protection against Escherichia coli K1 caused meningitis in mice. J Nanobiotechnology 2021;19:69. [PMID: 33673858 DOI: 10.1186/s12951-021-00812-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Michiyuki S, Tomita N, Mori Y, Kanda H, Tashiro K, Notomi T. Discrimination of a single nucleotide polymorphism in the haptoglobin promoter region, rs5472, using a competitive fluorophore-labeled probe hybridization assay following loop-mediated isothermal amplification. Biosci Biotechnol Biochem 2021;85:359-68. [PMID: 33604636 DOI: 10.1093/bbb/zbaa012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Waki K, Yokomizo K, Yoshiyama K, Takamori S, Komatsu N, Yamada A. Integrity of circulating cell-free DNA as a prognostic biomarker for vaccine therapy in patients with nonsmall cell lung cancer. Immunopharmacol Immunotoxicol 2021;43:176-82. [PMID: 33541161 DOI: 10.1080/08923973.2021.1872619] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Waki K, Yokomizo K, Kawano K, Tsuda N, Komatsu N, Yamada A. Integrity of plasma cell-free DNA as a prognostic factor for vaccine therapy in patients with endometrial cancer. Mol Clin Oncol 2021;14:29. [PMID: 33414910 DOI: 10.3892/mco.2020.2191] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Hashemzadeh P, Ghorbanzadeh V, Dariushnejad H. Predicted peptide-based MHC-I, MHC-II, CTL and B-cell epitopes of MUC-1 by immunoinformatics methods: a clue for novel multi-epitope vaccine development against breast cancer. Minerva Biotecnol 2020;32. [DOI: 10.23736/s1120-4826.19.02598-9] [Reference Citation Analysis]
17 Dong S, Subramanian S, Parent KN, Chen M. Promotion of CTL epitope presentation by a nanoparticle with environment-responsive stability and phagolysosomal escape capacity. J Control Release 2020;328:653-64. [PMID: 32961248 DOI: 10.1016/j.jconrel.2020.09.033] [Reference Citation Analysis]
18 Saadeldin MK, Abdel-Aziz AK, Abdellatif A. Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis. Med Hypotheses 2021;146:110365. [PMID: 33221134 DOI: 10.1016/j.mehy.2020.110365] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
19 Ma Y, Tang K, Zhang Y, Zhang C, Cheng L, Zhang F, Zhuang R, Jin B, Zhang Y. Protective CD8+ T-cell response against Hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1/Kb transgenic mice. Virol J 2020;17:146. [PMID: 33028368 DOI: 10.1186/s12985-020-01421-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Dehbarez FM, Nezafat N, Mahmoodi S. In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma. LDDD 2020;17:1164-1176. [DOI: 10.2174/1570180817999200502030038] [Reference Citation Analysis]
21 Zhao X, Yang F, Mariz F, Osen W, Bolchi A, Ottonello S, Müller M. Combined prophylactic and therapeutic immune responses against human papillomaviruses induced by a thioredoxin-based L2-E7 nanoparticle vaccine. PLoS Pathog 2020;16:e1008827. [PMID: 32886721 DOI: 10.1371/journal.ppat.1008827] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
22 Zhang L, Jiang C, Chen X, Gu J, Song Q, Zhong H, Xiong S, Dong Q, Yu JC, Deng N. Large-scale production, purification, and function of a tumor multi-epitope vaccine: Peptibody with bFGF/VEGFA. Eng Life Sci 2020;20:422-36. [PMID: 32944017 DOI: 10.1002/elsc.202000020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Zhang H, Zhou X, Liu D, Zhu Y, Ma Q, Zhang Y. Progress and challenges of personalized neoantigens in the clinical treatment of tumors. Medicine in Drug Discovery 2020;6:100030. [DOI: 10.1016/j.medidd.2020.100030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Waki K, Yokomizo K, Kawano K, Tsuda N, Komatsu N, Yamada A. Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients. Cancer Immunol Immunother 2020;69:2001-7. [PMID: 32393999 DOI: 10.1007/s00262-020-02599-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
25 Reustle A, Di Marco M, Meyerhoff C, Nelde A, Walz JS, Winter S, Kandabarau S, Büttner F, Haag M, Backert L, Kowalewski DJ, Rausch S, Hennenlotter J, Stühler V, Scharpf M, Fend F, Stenzl A, Rammensee HG, Bedke J, Stevanović S, Schwab M, Schaeffeler E. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy. Genome Med 2020;12:32. [PMID: 32228647 DOI: 10.1186/s13073-020-00731-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
26 Waki K, Kawano K, Tsuda N, Komatsu N, Yamada A. CD4/CD8 ratio is a prognostic factor in IgG nonresponders among peptide vaccine-treated ovarian cancer patients. Cancer Sci 2020;111:1124-31. [PMID: 32058620 DOI: 10.1111/cas.14349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Sabeerabi B, Arva Tatireddygari VR, Vadde R. Therapeutic Vaccines for Gastrointestinal Malignancies. Immunotherapy for Gastrointestinal Malignancies 2020. [DOI: 10.1007/978-981-15-6487-1_8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Rahat MA. Targeting Angiogenesis With Peptide Vaccines. Front Immunol 2019;10:1924. [PMID: 31440262 DOI: 10.3389/fimmu.2019.01924] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
29 Bazmara S, Shadmani M, Ghasemnejad A, Aghazadeh H, Pooshang Bagheri K. In silico rational design of a novel tetra-epitope tetanus vaccine with complete population coverage using developed immunoinformatics and surface epitope mapping approaches. Med Hypotheses 2019;130:109267. [PMID: 31383332 DOI: 10.1016/j.mehy.2019.109267] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
30 Koster J, Plasterk RHA. A library of Neo Open Reading Frame peptides (NOPs) as a sustainable resource of common neoantigens in up to 50% of cancer patients. Sci Rep 2019;9:6577. [PMID: 31036835 DOI: 10.1038/s41598-019-42729-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
31 Hazama S. Revolution in Cancer Immunotherapy and its Perspective. Yamaguchi Medical Journal 2019;68:5-12. [DOI: 10.2342/ymj.68.5] [Reference Citation Analysis]
32 Mahmoodi S, Nezafat N. In Silico Designing a Novel Multi-epitope DNA Vaccine against Anti-apoptotic Proteins in Tumor Cells. CP 2019;16:222-30. [DOI: 10.2174/1570164616666181127142214] [Reference Citation Analysis]
33 dos Santos Rodrigues B, Lakkadwala S, Sharma D, Singh J. Chitosan for gene, DNA vaccines, and drug delivery. Materials for Biomedical Engineering 2019. [DOI: 10.1016/b978-0-12-818433-2.00015-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Kyeong HH, Choi Y, Kim HS. GradDock: rapid simulation and tailored ranking functions for peptide-MHC Class I docking. Bioinformatics 2018;34:469-76. [PMID: 28968726 DOI: 10.1093/bioinformatics/btx589] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
35 Liang Z, Lu Z, Zhang Y, Shang D, Li R, Liu L, Zhao Z, Zhang P, Lin Q, Feng C, Zhang Y, Liu P, Tu Z, Liu H. Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy. Curr Cancer Drug Targets 2019;19:449-67. [PMID: 30306870 DOI: 10.2174/1568009618666181010091246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
36 Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology 2018;7:e1511506. [PMID: 30524907 DOI: 10.1080/2162402X.2018.1511506] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 17.8] [Reference Citation Analysis]
37 Kametani Y, Miyamoto A, Seki T, Ito R, Habu S, Tokuda Y. Significance of humanized mouse models for evaluating humoral immune response against cancer vaccines. Personalized Medicine Universe 2018;7:13-18. [DOI: 10.1016/j.pmu.2018.04.002] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Hazama S, Tamada K, Yamaguchi Y, Kawakami Y, Nagano H. Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy. Ann Gastroenterol Surg. 2018;2:289-303. [PMID: 30003192 DOI: 10.1002/ags3.12180] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
39 Sonntag K, Hashimoto H, Eyrich M, Menzel M, Schubach M, Döcker D, Battke F, Courage C, Lambertz H, Handgretinger R, Biskup S, Schilbach K. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. J Transl Med 2018;16:23. [PMID: 29409514 DOI: 10.1186/s12967-018-1382-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
40 Zhang L, He D, Huang J, Deng Y, Weng R, Pan L, Deng N. The Immunogenicity and Immunoprotection of VBP3 Multi-epitope Vaccine Targeting Angiogenesis and Tumor Inhibition in Lung Cancer-Bearing Mice. Int J Pept Res Ther 2019;25:215-25. [DOI: 10.1007/s10989-017-9667-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Wei C, Pohorille A. Sequence-Dependent Interfacial Adsorption and Permeation of Dipeptides across Phospholipid Membranes. J Phys Chem B 2017;121:9859-67. [PMID: 28982244 DOI: 10.1021/acs.jpcb.7b08238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Mochizuki S, Morishita H, Sakurai K. Complex Consisting of β-Glucan and Antigenic Peptides with Cleavage Site for Glutathione and Aminopeptidases Induces Potent Cytotoxic T Lymphocytes. Bioconjug Chem 2017;28:2246-53. [PMID: 28738674 DOI: 10.1021/acs.bioconjchem.7b00159] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
43 Shen J, Wang LF, Zou ZY, Kong WW, Yan J, Meng FY, Chen FJ, Du J, Shao J, Xu QP, Ren HZ, Li RT, Wei J, Qian XP, Liu BR. Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma. World J Gastroenterol 2017; 23(29): 5395-5404 [PMID: 28839440 DOI: 10.3748/wjg.v23.i29.5395] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
44 Afridi S, Hoessli DC, Hameed MW. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. Immunol Rev 2016;272:151-68. [PMID: 27319349 DOI: 10.1111/imr.12435] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
45 Dong S, Xu T, Wang P, Zhao P, Chen M. Engineering of a self-adjuvanted iTEP-delivered CTL vaccine. Acta Pharmacol Sin 2017;38:914-23. [PMID: 28414197 DOI: 10.1038/aps.2017.31] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
46 Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Sugawara S, Takamori S, Itoh K, Yamada A. Single nucleotide polymorphisms of the haptoglobin gene in non-small cell lung cancer treated with personalized peptide vaccination. Oncol Lett 2017;13:993-9. [PMID: 28356990 DOI: 10.3892/ol.2016.5467] [Reference Citation Analysis]
47 Xiang B, Baybutt TR, Berman-Booty L, Magee MS, Waldman SA, Alexeev VY, Snook AE. Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8+ T Cells. J Immunol 2017;198:3507-14. [PMID: 28341670 DOI: 10.4049/jimmunol.1502672] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
48 Kobayashi Y, Sakura T, Miyawaki S, Toga K, Sogo S, Heike Y. A new peptide vaccine OCV-501: in vitro pharmacology and phase 1 study in patients with acute myeloid leukemia. Cancer Immunol Immunother 2017;66:851-63. [PMID: 28321480 DOI: 10.1007/s00262-017-1981-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
49 Budama-kilinc Y, Ozdemir B, Gozutok K. Peptide-based nanobiomaterials. Nanobiomaterials Science, Development and Evaluation 2017. [DOI: 10.1016/b978-0-08-100963-5.00007-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
50 Waki K, Yamada A. Blockade of high mobility group box 1 augments antitumor T-cell response induced by peptide vaccination as a co-adjuvant. Cancer Sci 2016;107:1721-9. [PMID: 27717108 DOI: 10.1111/cas.13084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
51 Govea-alonso DO, Beltrán-lópez J, Salazar-gonzález JA, Vargas-morales J, Rosales-mendoza S. Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Review of Vaccines 2016;16:337-50. [DOI: 10.1080/14760584.2017.1258309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
52 Mathur D, Prakash S, Anand P, Kaur H, Agrawal P, Mehta A, Kumar R, Singh S, Raghava GP. PEPlife: A Repository of the Half-life of Peptides. Sci Rep 2016;6:36617. [PMID: 27819351 DOI: 10.1038/srep36617] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 11.3] [Reference Citation Analysis]
53 Kapadia CH, Tian S, Perry JL, Luft JC, DeSimone JM. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs. Mol Pharm 2016;13:3381-94. [PMID: 27551741 DOI: 10.1021/acs.molpharmaceut.6b00288] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
54 Zhang X, Sharma PK, Peter Goedegebuure S, Gillanders WE. Personalized cancer vaccines: Targeting the cancer mutanome. Vaccine 2017;35:1094-100. [PMID: 27449681 DOI: 10.1016/j.vaccine.2016.05.073] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 5.9] [Reference Citation Analysis]
55 Qian DC, Xiao X, Byun J, Suriawinata AA, Her SC, Amos CI, Barth RJ Jr. PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer. Clin Cancer Res 2017;23:399-406. [PMID: 27435399 DOI: 10.1158/1078-0432.CCR-16-0623] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
56 Duvallet E, Boulpicante M, Yamazaki T, Daskalogianni C, Prado Martins R, Baconnais S, Manoury B, Fahraeus R, Apcher S. Exosome-driven transfer of tumor-associated Pioneer Translation Products (TA-PTPs) for the MHC class I cross-presentation pathway. Oncoimmunology 2016;5:e1198865. [PMID: 27757298 DOI: 10.1080/2162402X.2016.1198865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
57 Guidance Development Review Committee., Working Group for Clinical Studies of Cancer Immunotherapy., Working Group for Effector Cell Therapy., Working Group for CMC/Non-clinical Studies., Working Group for Cancer Vaccines and Adjuvants., Working Group for Anti-immune Checkpoint Therapy and Comprehensive Cancer Immunotherapy., Biostatistics Subcommittee. 2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Sci 2015;106:1761-71. [PMID: 26767933 DOI: 10.1111/cas.12819] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
58 Tabaei S, Mashkani B, Esmaili A, Karimi R, Jamehdar SA. Design of cocktail peptide vaccine against Cytomegalovirus infection. Iran J Basic Med Sci 2016;19:449-54. [PMID: 27279990] [Reference Citation Analysis]
59 Sakamoto S, Noguchi M, Yamada A, Itoh K, Sasada T. Prospect and progress of personalized peptide vaccinations for advanced cancers. Expert Opin Biol Ther 2016;16:689-98. [PMID: 26938083 DOI: 10.1517/14712598.2016.1161752] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
60 Dong S, Xu T, Zhao P, Parent KN, Chen M. A Comparison Study of iTEP Nanoparticle-Based CTL Vaccine Carriers Revealed a Surprise Relationship between the Stability and Efficiency of the Carriers. Theranostics 2016;6:666-78. [PMID: 27022414 DOI: 10.7150/thno.14068] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
61 Fenoglio D, Parodi A, Lavieri R, Kalli F, Ferrera F, Tagliamacco A, Guastalla A, Lamperti MG, Giacomini M, Filaci G. Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Hum Vaccin Immunother 2015;11:838-50. [PMID: 25714118 DOI: 10.1080/21645515.2015.1012032] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
62 Wang H, Luo Z, Wang Y, He T, Yang C, Ren C, Ma L, Gong C, Li X, Yang Z. Enzyme-Catalyzed Formation of Supramolecular Hydrogels as Promising Vaccine Adjuvants. Adv Funct Mater 2016;26:1822-9. [DOI: 10.1002/adfm.201505188] [Cited by in Crossref: 137] [Cited by in F6Publishing: 135] [Article Influence: 19.6] [Reference Citation Analysis]
63 Molino NM, Neek M, Tucker JA, Nelson EL, Wang SW. Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses. Biomaterials 2016;86:83-91. [PMID: 26894870 DOI: 10.1016/j.biomaterials.2016.01.056] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 7.9] [Reference Citation Analysis]
64 Hjálmsdóttir Á, Bühler C, Vonwil V, Roveri M, Håkerud M, Wäckerle-Men Y, Gander B, Johansen P. Cytosolic Delivery of Liposomal Vaccines by Means of the Concomitant Photosensitization of Phagosomes. Mol Pharm 2016;13:320-9. [PMID: 26704885 DOI: 10.1021/acs.molpharmaceut.5b00394] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
65 Noguchi M. Personalized Peptide Vaccine. Immunotherapy of Cancer 2016. [DOI: 10.1007/978-4-431-55031-0_11] [Reference Citation Analysis]
66 Bernatchez C, Cooper ZA, Wargo JA, Hwu P, Lizée G. Novel Treatments in Development for Melanoma. Melanoma 2016. [DOI: 10.1007/978-3-319-22539-5_16] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
67 Kapadia CH, Perry JL, Tian S, Luft JC, Desimone JM. Nanoparticulate immunotherapy for cancer. Journal of Controlled Release 2015;219:167-80. [DOI: 10.1016/j.jconrel.2015.09.062] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]
68 NoeDominguez-Romero A, Zamora-Alvarado R, Servín-Blanco R, Pérez-Hernández EG, Castrillon-Rivera LE, Munguia ME, Acero G, Govezensky T, Gevorkian G, Manoutcharian K. Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Hum Vaccin Immunother 2014;10:3201-13. [PMID: 25483665 DOI: 10.4161/hv.29679] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
69 Xiao YF, Jie MM, Li BS, Hu CJ, Xie R, Tang B, Yang SM. Peptide-Based Treatment: A Promising Cancer Therapy. J Immunol Res 2015;2015:761820. [PMID: 26568964 DOI: 10.1155/2015/761820] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 9.5] [Reference Citation Analysis]
70 Araki H, Pang X, Komatsu N, Soejima M, Miyata N, Takaki M, Muta S, Sasada T, Noguchi M, Koda Y, Itoh K, Kuhara S, Tashiro K. Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients. Cancer Immunol Immunother 2015;64:1565-73. [PMID: 26428930 DOI: 10.1007/s00262-015-1756-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
71 Kametani Y, Miyamoto A, Tsuda B, Tokuda Y. B Cell Epitope-Based Vaccination Therapy. Antibodies 2015;4:225-39. [DOI: 10.3390/antib4030225] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
72 Baxevanis CN, Perez SA. Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant State. Vaccines (Basel) 2015;3:597-619. [PMID: 26350597 DOI: 10.3390/vaccines3030597] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
73 Chen J, Zurawski G, Zurawski S, Wang Z, Akagawa K, Oh S, Hideki U, Fay J, Banchereau J, Song W, Palucka AK. A novel vaccine for mantle cell lymphoma based on targeting cyclin D1 to dendritic cells via CD40. J Hematol Oncol 2015;8:35. [PMID: 25888530 DOI: 10.1186/s13045-015-0131-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
74 Markman JL, Shiao SL. Impact of the immune system and immunotherapy in colorectal cancer. J Gastrointest Oncol. 2015;6:208-223. [PMID: 25830040 DOI: 10.3978/j.issn.2078-6891.2014.077] [Cited by in F6Publishing: 77] [Reference Citation Analysis]
75 Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M. Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics 2015;14:658-73. [PMID: 25576301 DOI: 10.1074/mcp.M114.042812] [Cited by in Crossref: 299] [Cited by in F6Publishing: 303] [Article Influence: 37.4] [Reference Citation Analysis]
76 Avendaño C, Menéndez JC. Biological Therapy of Cancer. Medicinal Chemistry of Anticancer Drugs 2015. [DOI: 10.1016/b978-0-444-62649-3.00012-0] [Reference Citation Analysis]
77 Houen G. Peptide Antibodies: Past, Present, and Future. Methods in Molecular Biology 2015. [DOI: 10.1007/978-1-4939-2999-3_1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
78 Liu X, Kline J. Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines). Immunopharmacogenomics 2015. [DOI: 10.1007/978-4-431-55726-5_4] [Reference Citation Analysis]
79 Håkerud M, Selbo PK, Waeckerle-men Y, Contassot E, Dziunycz P, Kündig TM, Høgset A, Johansen P. Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells. Journal of Controlled Release 2015;198:10-7. [DOI: 10.1016/j.jconrel.2014.11.032] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
80 Harao M, Mittendorf EA, Radvanyi LG. Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer. BioDrugs 2015;29:15-30. [DOI: 10.1007/s40259-014-0114-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
81 Vandermeulen G, Uyttenhove C, De Plaen E, Van den Eynde BJ, Préat V. Intramuscular electroporation of a P1A-encoding plasmid vaccine delays P815 mastocytoma growth. Bioelectrochemistry 2014;100:112-8. [DOI: 10.1016/j.bioelechem.2013.11.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
82 Skwarczynski M, Toth I. Recent advances in peptide-based subunit nanovaccines. Nanomedicine 2014;9:2657-69. [DOI: 10.2217/nnm.14.187] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 15.0] [Reference Citation Analysis]
83 Nezafat N, Sadraeian M, Rahbar MR, Khoshnoud MJ, Mohkam M, Gholami A, Banihashemi M, Ghasemi Y. Production of a novel multi-epitope peptide vaccine for cancer immunotherapy in TC-1 tumor-bearing mice. Biologicals 2015;43:11-7. [PMID: 25467837 DOI: 10.1016/j.biologicals.2014.11.001] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
84 Zhang Q, Lao X, Huang J, Zhu Z, Pang L, Tang Y, Song Q, Huang J, Deng J, Deng N, Yang Q, Sengupta AM, Xiong L. Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide. Biotechnol Prog 2015;31:194-203. [PMID: 25271020 DOI: 10.1002/btpr.1997] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
85 Ekkirala CR, Cappello P, Accolla RS, Giovarelli M, Romero I, Garrido C, Garcia-Lora AM, Novelli F. Class II transactivator-induced MHC class II expression in pancreatic cancer cells leads to tumor rejection and a specific antitumor memory response. Pancreas 2014;43:1066-72. [PMID: 24987872 DOI: 10.1097/MPA.0000000000000160] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
86 Waki K, Yamada T, Yoshiyama K, Terazaki Y, Sakamoto S, Matsueda S, Komatsu N, Sugawara S, Takamori S, Itoh K, Yamada A. PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer. Cancer Sci 2014;105:1229-35. [PMID: 25117757 DOI: 10.1111/cas.12502] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
87 Baxevanis CN, Papamichail M, Perez SA. Therapeutic cancer vaccines: a long and winding road to success. Expert Rev Vaccines 2014;13:131-44. [PMID: 24224539 DOI: 10.1586/14760584.2014.852961] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
88 Soysal SD, Muenst S, Kan-Mitchell J, Huarte E, Zhang X, Wilkinson-Ryan I, Fleming T, Tiriveedhi V, Mohanakumar T, Li L, Herndon J, Oertli D, Goedegebuure SP, Gillanders WE. Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes. Breast Cancer Res Treat 2014;147:527-37. [PMID: 25212176 DOI: 10.1007/s10549-014-3129-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
89 Uhlig T, Kyprianou T, Martinelli FG, Oppici CA, Heiligers D, Hills D, Calvo XR, Verhaert P. The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open Proteomics 2014;4:58-69. [DOI: 10.1016/j.euprot.2014.05.003] [Cited by in Crossref: 304] [Cited by in F6Publishing: 182] [Article Influence: 33.8] [Reference Citation Analysis]
90 Kaumaya PT. Bridging oncology and immunology: expanding horizons with innovative peptide vaccines and peptidomimetics. Immunotherapy 2013;5:1159-63. [PMID: 24188668 DOI: 10.2217/imt.13.128] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
91 Kissick HT, Sanda MG, Dunn LK, Arredouani MS. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PLoS One 2014;9:e93231. [PMID: 24690990 DOI: 10.1371/journal.pone.0093231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
92 Tosti G, Cocorocchio E, Pennacchioli E, Ferrucci PF, Testori A, Martinoli C. Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opin Biol Ther 2014;14:955-67. [PMID: 24670226 DOI: 10.1517/14712598.2014.902928] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
93 Lollini P, Cavallo F, De Giovanni C, Nanni P. Preclinical vaccines against mammary carcinoma. Expert Review of Vaccines 2014;12:1449-63. [DOI: 10.1586/14760584.2013.845530] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
94 Ni B, Jia Z, Wu Y. Preparation of Polypeptides Comprising Multiple TAA Peptides. Methods in Molecular Biology 2014. [DOI: 10.1007/978-1-4939-0345-0_29] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
95 Watanabe M, Nasu Y, Kumon H. Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncol Lett 2014;7:595-601. [PMID: 24527065 DOI: 10.3892/ol.2013.1777] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
96 Jiménez-Periáñez A, Abos Gracia B, López Relaño J, Diez-Rivero CM, Reche PA, Martínez-Naves E, Matveyeva E, Gómez del Moral M. Mesoporous silicon microparticles enhance MHC class I cross-antigen presentation by human dendritic cells. Clin Dev Immunol 2013;2013:362163. [PMID: 24324504 DOI: 10.1155/2013/362163] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
97 Sant AJ, Chaves FA, Leddon SA, Tung J. The control of the specificity of CD4 T cell responses: thresholds, breakpoints, and ceilings. Front Immunol 2013;4:340. [PMID: 24167504 DOI: 10.3389/fimmu.2013.00340] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
98 Deschoolmeester V, Smits E, Peeters M, Vermorken JB. Status of Active Specific Immunotherapy for Stage II, Stage III, and Resected Stage IV Colon Cancer. Curr Colorectal Cancer Rep 2013;9:380-90. [DOI: 10.1007/s11888-013-0182-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
99 Fenoglio D, Traverso P, Parodi A, Kalli F, Zanetti M, Filaci G. Generation of more effective cancer vaccines. Hum Vaccin Immunother 2013;9:2543-7. [PMID: 23978951 DOI: 10.4161/hv.26147] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
100 Arens R, van Hall T, van der Burg SH, Ossendorp F, Melief CJ. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Semin Immunol 2013;25:182-90. [PMID: 23706598 DOI: 10.1016/j.smim.2013.04.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]